Physician profile
Nicole Morgan
NPI 1083100036
$6,535.64
in general payments reported to CMS, 2019-2025
40 companies · $4,685 in 2025
The $4,685 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,851 · 2025: $4,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,485 · Travel and Lodging: $3,031 · Gift: $19.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,484.64 |
| Travel and Lodging | $3,031.26 |
| Gift | $19.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onmark, INC. | $3,542.69 | 2025 | |
| Abbvie INC. | $1,467.75 | 2024-2025 | |
| Janssen Biotech, INC. | $146.38 | 2025 | Rybrevant, Talvey, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $119.43 | 2024-2025 | Enhertu |
| Lilly USA, LLC | $108.35 | 2024-2025 | Jaypirca, Verzenio |
| Novartis Pharmaceuticals Corporation | $99.37 | 2024-2025 | |
| Daiichi Sankyo INC. | $97.35 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Tersera Therapeutics LLC | $62.56 | 2024-2025 | Zoladex |
| Pharmaessentia USA Corporation | $59.84 | 2024-2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $58.56 | 2024-2025 | Alunbrig, Fruzaqla, Iclusig |
| E.R. Squibb & Sons, L.L.C. | $57.19 | 2025 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $48.69 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Genzyme Corporation | $48.08 | 2025 | |
| Eisai INC. | $42.82 | 2025 | |
| Adc Therapeutics America, INC. | $35.43 | 2024-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.